Intranasal Corticosteroids for Acute Sinus Infection
Intranasal corticosteroids should be used as adjunctive therapy to antibiotics in acute bacterial rhinosinusitis, particularly in patients with a history of allergic rhinitis, and may also be considered as monotherapy in uncomplicated cases. 1
Guideline-Based Recommendations
Primary Recommendation
The IDSA (Infectious Diseases Society of America) recommends intranasal corticosteroids as an adjunct to antibiotics in the empiric treatment of acute bacterial rhinosinusitis (ABRS), with the strongest benefit seen in patients with a history of allergic rhinitis (weak recommendation, moderate quality evidence). 1
The American Academy of Otolaryngology-Head and Neck Surgery supports the use of topical intranasal steroids for symptomatic relief in ABRS, acknowledging their role in reducing inflammation and associated symptoms. 1
Evidence of Efficacy
Symptom Improvement:
Intranasal corticosteroids increase the rate of symptom resolution or improvement from 66% to 73% at 15-21 days (number needed to treat = 14). 2
The therapeutic benefit is modest but clinically important, with a risk ratio of 1.11 (95% CI: 1.04-1.18) for symptom improvement compared to placebo. 2, 3
Dose-Response Relationship:
Higher doses demonstrate stronger effects: mometasone furoate 400 µg shows superior efficacy compared to 200 µg (RR 1.10 vs 1.04). 2, 4
Meta-regression analysis confirms a significant dose-response relationship (P=0.02). 3
Specific Symptom Relief:
The most consistent benefits are seen for facial pain and nasal congestion. 3
Benefits appear greater with 21-day courses (RD = 0.11) compared to 14-15 day courses (RD = 0.05, not statistically significant). 3
Clinical Application Algorithm
When to Use Intranasal Corticosteroids:
As Adjunctive Therapy (Preferred Approach):
- Combine with antibiotics (amoxicillin-clavulanate) in patients with confirmed ABRS, especially those with allergic rhinitis history. 1
- Duration: 15-21 days for optimal benefit. 2, 3
- Dose: Higher doses (e.g., mometasone furoate 400 µg daily) provide greater symptom relief. 2, 4
As Monotherapy:
- May be considered in uncomplicated acute sinusitis, though evidence is more limited in antibiotic-naïve patients. 3, 5
- One trial showed mometasone furoate 200 µg twice daily produced greater symptom improvements than amoxicillin or placebo in uncomplicated cases. 5
Contraindicated Approach:
- Do NOT use oral/systemic corticosteroids as monotherapy for ABRS—no proven benefit and potential for adverse events. 1
Important Caveats and Pitfalls
Safety Profile:
- Adverse events are minor and include epistaxis, headache, and nasal itching. 2, 4
- No significant difference in drop-out rates or recurrence compared to placebo. 2, 4
Evidence Limitations:
Most trials included patients receiving concurrent antibiotics, limiting generalizability to antibiotic-naïve populations. 3
One high-quality trial (Williamson et al.) found no benefit for budesonide with or without amoxicillin, but this study likely included many viral rhinosinusitis cases (median symptom duration 7 days). 6
The evidence base includes heterogeneous populations (viral, bacterial, recurrent cases), which may dilute observed effects. 1
What NOT to Use:
Oral antihistamines and decongestants are NOT recommended as adjunctive treatment in ABRS (strong recommendation). 1
Systemic corticosteroids show no benefit as monotherapy and limited, uncertain benefit when combined with antibiotics. 1
Complementary Therapies
Intranasal saline irrigation (physiologic or hypertonic) is recommended as adjunctive treatment in adults with ABRS and can be used alongside intranasal corticosteroids. 1